Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics
Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Y-Mabs Therapeutics (YMAB – Research Report). The associated price ...
Analysts Issue Forecasts for YMAB FY2024 Earnings
Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...
Promising Preclinical Results of Y-Mabs Therapeutics’ CD38 SADA Platform Justify Buy Rating
Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...
ETF Daily News5d
Y-mAbs Therapeutics (NASDAQ:YMAB) Now Covered by Brookline Capital Management
Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...
Hosted on MSN7d
Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy Recommendation
Fintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a ...
Taiwan News15d
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
Morningstar15d
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company ...